David Deming has over thirty years experience in investment banking. He has focused on the healthcare industry for over 15 years, including 12 years as the leader of JP Morgan’s Healthcare Investment Banking Group. His experience includes mergers & acquisitions advice, strategic partnerships, capital raising, and general financial advice for pharmaceutical, biotech, medical device companies, and service companies.
Some of Mr. Deming’s former client assignments were for Johnson & Johnson, Baxter International, Gilead Sciences, Scios Pharmaceuticals, CV Therapeutics, Celgene Corporation and Tenet Healthcare. Mr. Deming also has significant experience working with Japanese clients including Chugai Pharmaceutical Co., Eisai Co., Fujisawa Pharmaceutical Co., and Mitsubishi Tanabe Pharma.
Mr. Deming founded TAG Healthcare Advisors in 2013. Prior to this role, he was the CEO of a start-up pension management business, SmartNest LLC, which was successfully sold in 2010. He previously spent over 27 years at JP Morgan Chase and JP Morgan where he conducted M&A across industries before joining the healthcare investment banking effort. Mr. Deming served as head of the global healthcare investment banking team for 12 years. Mr. Deming graduated from Hobart College with a BA in Economics with Highest Honors.
Mr. Deming is a member of the Board of Directors of the following companies: Celularity, Cutanea Life Sciences, IRX Therapeutics, and Sorrento Therapeutics.
None of the information contained in this web site constitutes a recommendation, solicitation or offer by Alberleen or its affiliates to buy or sell any securities or other financial instruments of any person or provide any investment advice or service. All securities are offered exclusively through Cuttone & Co., LLC, a broker-dealer member of FINRA and SIPC.